Search research articles
Contact Us
Filters
Showing results (71-80 of 105) with videos related to
Page
of 11
Sort By:
The Lancet. Oncology
|
September 15, 2014
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F Liu, William T Barry, Michael Birrer, et al.
Cancers
|
June 2, 2021
Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient <i>TP53</i> Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 Interactions
Katherine N Lynch, Joyce F Liu, Nikolas Kesten, et al.
Science Translational Medicine
|
August 17, 2012
Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4
Yin Ren, Hiu Wing Cheung, Geoffrey von Maltzhan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2019
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
Kalindi Parmar, Bose S Kochupurakkal, Jean-Bernard Lazaro, et al.
Nature Communications
|
March 27, 2026
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial
Rebecca L Porter, Yinglu Zhou, Nebiyat Eskndir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 29, 2022
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer
Panagiotis A Konstantinopoulos, Elizabeth K Lee, Niya Xiong, et al.
Gynecologic Oncology Reports
|
April 18, 2022
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma
Elizabeth H Stover, Niya Xiong, Andrea P Myers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 22, 2024
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study
Charles N Landen, Ronald J Buckanovich, Michael W Sill, et al.
JCO Precision Oncology
|
April 10, 2025
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer
Panagiotis A Konstantinopoulos, Mingyang Cai, Elizabeth K Lee, et al.
Elife
|
November 14, 2018
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
Mei Zeng, Nicholas P Kwiatkowski, Tinghu Zhang, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 105) with videos related to
Sort By:
Page
of 11
The Lancet. Oncology
|
September 15, 2014
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F Liu, William T Barry, Michael Birrer, et al.
Cancers
|
June 2, 2021
Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient <i>TP53</i> Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 Interactions
Katherine N Lynch, Joyce F Liu, Nikolas Kesten, et al.
Science Translational Medicine
|
August 17, 2012
Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4
Yin Ren, Hiu Wing Cheung, Geoffrey von Maltzhan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2019
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
Kalindi Parmar, Bose S Kochupurakkal, Jean-Bernard Lazaro, et al.
Nature Communications
|
March 27, 2026
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial
Rebecca L Porter, Yinglu Zhou, Nebiyat Eskndir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 29, 2022
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer
Panagiotis A Konstantinopoulos, Elizabeth K Lee, Niya Xiong, et al.
Gynecologic Oncology Reports
|
April 18, 2022
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma
Elizabeth H Stover, Niya Xiong, Andrea P Myers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 22, 2024
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study
Charles N Landen, Ronald J Buckanovich, Michael W Sill, et al.
JCO Precision Oncology
|
April 10, 2025
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer
Panagiotis A Konstantinopoulos, Mingyang Cai, Elizabeth K Lee, et al.
Elife
|
November 14, 2018
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
Mei Zeng, Nicholas P Kwiatkowski, Tinghu Zhang, et al.
Page
of 11